These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 14585629)

  • 1. The statin wars: why AstraZeneca must retreat.
    Lancet; 2003 Oct; 362(9393):1341. PubMed ID: 14585629
    [No Abstract]   [Full Text] [Related]  

  • 2. The statin wars.
    McKillop T
    Lancet; 2003 Nov; 362(9394):1498. PubMed ID: 14602449
    [No Abstract]   [Full Text] [Related]  

  • 3. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
    Hirsch M; O'donnell J; Olsson A
    Int J Cardiol; 2005 Oct; 104(3):251-6. PubMed ID: 16186052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [By JUPITER! Disease mongering!].
    Welin L; Peterson M
    Lakartidningen; 2008 Dec; 105(51-52):3756; discussion 3756-7. PubMed ID: 19278103
    [No Abstract]   [Full Text] [Related]  

  • 5. Statin therapy for elevated hsCRP: more evidence is needed.
    Molokwu OC
    Am J Manag Care; 2010 Aug; 16(8):565-6. PubMed ID: 20712389
    [No Abstract]   [Full Text] [Related]  

  • 6. Statin therapy for elevated hsCRP: what are the public health implications?
    Ridker PM
    Am J Manag Care; 2010 Aug; 16(8):561-2. PubMed ID: 20712388
    [No Abstract]   [Full Text] [Related]  

  • 7. [JUPITER study about rosuvastatin and risk of cardiovascular disease. Unclear consequences for the guideline].
    Lubsen J
    Ned Tijdschr Geneeskd; 2009 Feb; 153(6):216-7. PubMed ID: 19271438
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial.
    Ohsfeldt RL; Gandhi SK; Smolen LJ; Jensen MM; Fox KM; Gold A; Hsia J
    J Med Econ; 2010; 13(3):428-37. PubMed ID: 20662625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER.
    Slejko JF; Page RL; Sullivan PW
    Curr Med Res Opin; 2010 Oct; 26(10):2485-97. PubMed ID: 20828360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
    Miller PS; Smith DG; Jones P
    Am J Cardiol; 2005 Jun; 95(11):1314-9. PubMed ID: 15904635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teva v. AstraZeneca and secret prior art under 102(g)(2).
    Lee S; Knierim M
    Nat Biotechnol; 2012 Sep; 30(9):831-3. PubMed ID: 22965051
    [No Abstract]   [Full Text] [Related]  

  • 12. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M; O'Donnell JC; Jones P
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of restricted reimbursement on the use of statins in Finland: a register-based study.
    Martikainen JE; Saastamoinen LK; Korhonen MJ; Enlund H; Helin-Salmivaara A
    Med Care; 2010 Sep; 48(9):761-6. PubMed ID: 20706164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein.
    MacDonald GP
    J Am Osteopath Assoc; 2010 Aug; 110(8):427-36. PubMed ID: 20805548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The statin wars.
    Dunselman P; Hjalmarson A; Kjekshus J; McMurray J; Waagstein F;
    Lancet; 2003 Nov; 362(9398):1854; discussion 1856. PubMed ID: 14654327
    [No Abstract]   [Full Text] [Related]  

  • 16. Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
    Montouchet C; Ruff L; Balu S
    J Med Econ; 2013 Jul; 16(7):907-16. PubMed ID: 23641809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
    Barrios V; Lobos JM; Serrano A; Brosa M; Capel M; Alvarez Sanz C
    J Med Econ; 2012; 15 Suppl 1():45-54. PubMed ID: 22954062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spinning stars: ASTEROID's impact on atherosclerosis.
    Schachter M; Wierzbicki AS
    Lancet; 2006 May; 367(9523):1655-6. PubMed ID: 16714182
    [No Abstract]   [Full Text] [Related]  

  • 19. Economic evaluation of a compliance-enhancing intervention in patients with hypercholesterolemia: design and baseline results of the Open Label Primary Care Study: Rosuvastatin Based Compliance Initiatives To Achievements of LDL Goals (ORBITAL) study.
    Willich SN; Müller-Nordhorn J; Sonntag F; Völler H; Meyer-Sabellek W; Wegscheider K; Windler E; Katus H
    Am Heart J; 2004 Dec; 148(6):1060-7. PubMed ID: 15632894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial.
    Ohsfeldt RL; Olsson AG; Jensen MM; Gandhi SK; Paulsson T
    J Med Econ; 2012; 15(1):125-33. PubMed ID: 22050473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.